Policy / Pricing The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMs Drug ChannelsBy Adam J.Read full story pharminent June 2, 2026 (Last updated: June 4, 2026) Drug Channels By Adam J. Read full story Post navigation Previous: ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancerNext: Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb Related Stories Policy / Pricing Mid-cap biotechs join Trump’s latest round of drug pricing deals pharminent September 1, 2026 Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026 Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026